Rocket Pharmaceuticals (NASDAQ:RCKT – Get Rating) had its price objective lowered by Chardan Capital from $63.00 to $61.00 in a research report issued to clients and investors on Friday, The Fly reports. Chardan Capital’s price target indicates a potential upside of 190.48% from the company’s previous close. A number of other research firms have also […]
StockNews.com upgraded shares of Rocket Pharmaceuticals (NASDAQ:RCKT – Get Rating) to a sell rating in a research report report published on Wednesday morning. A number of other equities analysts have also issued reports on RCKT. Morgan Stanley assumed coverage on shares of Rocket Pharmaceuticals in a research report on Wednesday, February 1st. They set an […]
StockNews.com upgraded shares of Rocket Pharmaceuticals (NASDAQ:RCKT – Get Rating) to a sell rating in a report released on Wednesday. A number of other equities research analysts have also weighed in on the stock. William Blair reiterated an outperform rating on shares of Rocket Pharmaceuticals in a research note on Wednesday, March 22nd. Needham & […]
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Rating) – William Blair issued their Q1 2023 earnings per share (EPS) estimates for Rocket Pharmaceuticals in a note issued to investors on Wednesday, March 22nd. William Blair analyst S. Corwin forecasts that the biotechnology company will post earnings of ($0.96) per share for the quarter. William Blair has […]
Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Rating) have been assigned a consensus rating of “Moderate Buy” from the fourteen brokerages that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and twelve have assigned a buy rating to the company. The average 1 […]